Expensify Inc vs FMC Corp — how do they compare? Expensify Inc trades at $1.8 (market cap $170.21M), while FMC Corp trades at $11.32 (market cap $1.36B). The key difference: FMC Corp is far larger — about 8× Expensify Inc's market cap, and FMC Corp pays a 2.95% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | FMC | |
|---|---|---|
Market Cap | $170.21M | $1.36B |
Sector | Technology | Basic Materials |
52-Week High | $2.33 | $43.90 |
52-Week Low | $0.75 | $10.72 |
Enterprise Value | $109.24M | $5.50B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.77, down 2.21% on the day, with a bullish technical signal from moving averages but mixed earnings history. Revenue for 2025 was $142.10M, but the company posted a net loss of -$21.39M, with negative profit margins and ROE. Recent news highlights product innovations like AI-powered expense automation and a $25M stock buyback program, indicating active management efforts to drive growth and shareholder value.
The outlook remains challenging due to persistent unprofitability, though positive cash flow from operations and strategic partnerships offer some stability. Investment opportunities hinge on successful execution of new AI and travel billing initiatives to improve margins. Key risks include intense competition in expense management software and the company's ability to achieve sustained profitability amid fluctuating revenues.
FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.
The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.
Trailing returns across standard periods
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →